Bizengri | pharmaphorum

Skip to main content

Tuesday 2 June 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Bizengri

News

Bizengri pack and vial

Partner's Bizengri is first drug for rare, aggressive cancer

Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.

News

Merus

Merus grabs first-in-class US approval for NRG1 cancer drug

Merus has its first approval for a commercial product, getting the go-ahead from the FDA for Bizengri, a first-in-class therapy for cancer

Editor's Picks

GBL joins CVC in €10.7bn takeover bid for Recordati

After refusing to resign, CDER head Høeg is fired

As Ebola deaths climb, search begins for vaccine

NICE changes stance on Genmab's cervical cancer drug

Remepy's hybrid Parkinson's therapy poised for phase 3

News

CEPI puts $60m behind three Ebola vaccine candidates

CEPI puts $60m behind three Ebola vaccine candidates

Moderna has been awarded $50m from CEPI for a Bundibugyo ebolavirus vaccine candidate, with funding also made available to two other candidates.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company